Latest News

Revance is a biotechnology company focused on innovative aesthetic and therapeutic offerings, as well as financial technology services for aesthetic practices.

Formulary Watch Logo

FDA Accepts Resubmitted BLA for Cosmetic Therapy

My Medical Daily Logo

FDA Accepts Revance Resubmission for Frown Line Therapy

Endpoint News Logo

Will A Biotech Rival Finally Shake Up Abbvie’s $2B Botox Cosmetic Franchise? Revance Will Find Out Soon

Fierce Farma Logo

Revance Set For September FDA Decision on Botox Rival

Plastic Surgery Practice logo

FDA Accepts Revance Resubmission for Frown Line Treatment

Med Esthetics Magazine logo

Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines